<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5278">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01151579</url>
  </required_header>
  <id_info>
    <org_study_id>ME 07-0011</org_study_id>
    <nct_id>NCT01151579</nct_id>
  </id_info>
  <brief_title>Effect of Nebulized Bronchodilators on Heart Rate</brief_title>
  <official_title>Prospective Trial of Effect of Nebulized Bronchodilators on Heart Rate and Arrhythmias in Critically Ill Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fahim Khorfan, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genesys Regional Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Genesys Regional Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine adverse events rates of nebulized albuterol versus
      levalbuterol among adult critically ill patients and determine if a differential exists in
      adverse events between the two drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, single-blind, cross-over, prospective study was conducted in seventy
      critically ill adult patients with acute air flow obstruction. Patients were randomized to
      nebulized albuterol alternating with levalbuterol every 4 to 6 hours. Group A received
      albuterol 2.5 mg alternating with levalbuterol 0.63 mg. Group B received albuterol 2.5 mg
      alternating with levalbuterol 1.25 mg. All patients received nebulized ipratropium bromide
      500 micrograms with each treatment. Heart rate and cardiac rhythm were continuously recorded
      before and 15 minutes after finishing each treatment. Any new rhythm abnormalities between
      treatments were also recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Heart Rate in Beats Per Minute</measure>
    <time_frame>Five days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Average difference in Heart rate between pre and post breathing treatments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arrhythmias</measure>
    <time_frame>15 minutes after each treatment for average of 3 to 5 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Any new arrhythmia documented in the medical record that occurred between breathing treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Participants With Arrhythmias</measure>
    <time_frame>Five days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Documented new arrhythmia occurring during study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>COPD</condition>
  <condition>Sepsis</condition>
  <condition>Shock</condition>
  <arm_group>
    <arm_group_label>Levalbuterol 0.63</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received an initial dose of levalbuterol 0.63 mg alternating with albuterol 2.5 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levalbuterol 1.25</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received an initial dose of levalbuterol 1.25 mg alternating with albuterol 2.5 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levalbuterol</intervention_name>
    <description>inhaled Levalbuterol 0.625 mg inhaled Levalbuterol 2.5 mg</description>
    <arm_group_label>Levalbuterol 0.63</arm_group_label>
    <arm_group_label>Levalbuterol 1.25</arm_group_label>
    <other_name>Xopenex</other_name>
    <other_name>ipratropium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol</intervention_name>
    <description>Nebulized albuterol 2.5mg</description>
    <arm_group_label>Levalbuterol 0.63</arm_group_label>
    <arm_group_label>Levalbuterol 1.25</arm_group_label>
    <other_name>Salbutamol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults who required inhaled bronchodilator therapy in the form of short acting beta
             adrenergic receptor agonist and short acting anti-cholinergic treatment every 4-6
             hours for respiratory functions

        Exclusion Criteria:

          -  Known allergy or sensitivity to study medications

          -  Baseline heart rate was greater than 110 beats per minute
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fahim Khorfan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Genesys Regional Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kimberly R Barber, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Genesys Regional Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Genesys Regional Medical Center</name>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <zip>48439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 23, 2015</lastchanged_date>
  <firstreceived_date>June 24, 2010</firstreceived_date>
  <firstreceived_results_date>March 12, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Genesys Regional Medical Center</investigator_affiliation>
    <investigator_full_name>Fahim Khorfan, MD</investigator_full_name>
    <investigator_title>ICU Pulmonologist</investigator_title>
  </responsible_party>
  <keyword>Tachycardia</keyword>
  <keyword>tachyarrhythmias</keyword>
  <keyword>bronchodilator therapy</keyword>
  <keyword>Critically ill patients</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Bronchodilator Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began initially August 21, 2007 at the medical center ICU.</recruitment_details>
      <pre_assignment_details>Patients were excluded if they had a known allergy or sensitivity to study medications or if baseline heart rate was greater than 110 bpm. Treating physicians detremined the need for and frequency of treatment with bronchodilator therapy. All other medications were allowed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nebulized Albuterol 2.5mg</title>
          <description>Patients were randomized to receive an initial dose of albuterol 2.5 mg alternating with levalbuterol 0.63 mg.</description>
        </group>
        <group group_id="P2">
          <title>Levalbuterol 1.25</title>
          <description>Patients received an initial dose of levalbuterol 1.25 mg alternating with albuterol 2.5 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not meet inclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The number analyzed was determined by the power calculation and based on the number of participants randomized to treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Nebulized Albuterol 2.5mg</title>
          <description>Patients were randomized to receive an initial dose of albuterol 2.5 mg alternating with levalbuterol 0.63 mg.</description>
        </group>
        <group group_id="B2">
          <title>Levalbuterol 1.25</title>
          <description>Patients received an initial dose of levalbuterol 1.25 mg alternating with albuterol 2.5 mg.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="58"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="89"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="27"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="62"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="67.3" spread="13.1"/>
                <measurement group_id="B2" value="67.5" spread="13.7"/>
                <measurement group_id="B3" value="67.3" spread="13.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="31"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="43"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="46"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="58"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="89"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Heart Rate in Beats Per Minute</title>
        <description>Average difference in Heart rate between pre and post breathing treatments</description>
        <time_frame>Five days</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Average change in heart rate from baseline to final breathing treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Nebulized Albuterol 2.5mg</title>
            <description>Patients were randomized to receive an initial dose of albuterol 2.5 mg alternating with levalbuterol 0.63 mg.</description>
          </group>
          <group group_id="O2">
            <title>Levalbuterol 1.25</title>
            <description>Patients received an initial dose of levalbuterol 1.25 mg alternating with albuterol 2.5 mg.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Breathing treatment episodes analyzed</title>
            <units>Breathing treatment episodes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="604"/>
                  <measurement group_id="O2" value="232"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Heart Rate in Beats Per Minute</title>
            <description>Average difference in Heart rate between pre and post breathing treatments</description>
            <units>bpm</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.16" spread="5.1"/>
                  <measurement group_id="O2" value="1.40" spread="5.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: No difference between groups in heart rate changes from baseline following treatment. Sample size calculation determined a need for at least 400 breathing treatments among 65 patients.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>A total of at least 400 treatemnts or 65 patients was required to achieve 94% power to determine a 1% change by treatment or a 5% change between groups to be significant at p-value of 0.01 and o.05, respectively.</non_inferiority_desc>
            <p_value>0.01</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arrhythmias</title>
        <description>Any new arrhythmia documented in the medical record that occurred between breathing treatments.</description>
        <time_frame>15 minutes after each treatment for average of 3 to 5 days</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The percentage of arrhythmias among the number of breathing treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Nebulized Albuterol 2.5mg</title>
            <description>Patients were randomized to receive an initial dose of albuterol 2.5 mg alternating with levalbuterol 0.63 mg.</description>
          </group>
          <group group_id="O2">
            <title>Levalbuterol 1.25</title>
            <description>Patients received an initial dose of levalbuterol 1.25 mg alternating with albuterol 2.5 mg.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Arrhythmias</title>
            <description>Any new arrhythmia documented in the medical record that occurred between breathing treatments.</description>
            <units>percent</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.33"/>
                  <measurement group_id="O2" value="1.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: no difference in incidence of arrhythmias between groups within the total number of breathing treatments.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.05</p_value>
            <p_value_desc>Analysis adjusted with Fischer exact chi-square for rare occurrences.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Participants With Arrhythmias</title>
        <description>Documented new arrhythmia occurring during study.</description>
        <time_frame>Five days</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Number of patients for whom arrhythmias occurred within 5 days after treatment initiation.</population>
        <group_list>
          <group group_id="O1">
            <title>Nebulized Albuterol 2.5mg</title>
            <description>Patients were randomized to receive an initial dose of albuterol 2.5 mg alternating with levalbuterol 0.63 mg.</description>
          </group>
          <group group_id="O2">
            <title>Levalbuterol 1.25</title>
            <description>Patients received an initial dose of levalbuterol 1.25 mg alternating with albuterol 2.5 mg.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Total Number of Participants With Arrhythmias</title>
            <description>Documented new arrhythmia occurring during study.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To report on the number of events.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0</p_value>
            <method>descriptive</method>
            <method_desc>Descriptive statistics (frequency) used to report the number of participants experiencing an event.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Within 5 days of treatment initiation and within 15 minutes of each individual treatment.</time_frame>
      <desc>Cardiac arrhythmia</desc>
      <group_list>
        <group group_id="E1">
          <title>Nebulized Albuterol 2.5mg</title>
          <description>Patients were randomized to receive an initial dose of albuterol 2.5 mg alternating with levalbuterol 0.63 mg.</description>
        </group>
        <group group_id="E2">
          <title>Levalbuterol 1.25</title>
          <description>Patients received an initial dose of levalbuterol 1.25 mg alternating with albuterol 2.5 mg.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <description>Cardiac arrhythmia as documented by healthcare provider.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Potential limitations are its single-center site and that the design may not have adequately eliminated all carryover effects from the levalbuterol. However, the number of side effects without carryover would be even lower than we observed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Fahim Khorfan</name_or_title>
      <organization>Genesys Regional Medical Center</organization>
      <phone>810-606-7722</phone>
      <email>kbarber@genesys.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
